SCHEMBL24596209

SCHEMBL24596209

CC(C)c1ccccc1Nc1nc(C(F)(F)F)ccc1Br

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 1/20 0.44
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
IGF1R P08069 2/20 0.39
EGFR P00533 2/20 0.39
JAK1 P23458 1/20 0.35
JAK3 P52333 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA9 Q16790 2/20 0.34
PDGFRB P09619 1/20 0.34
TSHR P16473 1/20 0.34
LMNA P02545 1/20 0.34
TAS2R14 Q9NYV8 2/20 0.33
CCNK O75909 1/20 0.33
CCND3 P30281 1/20 0.33
CDK9 P50750 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24596182 0.82 CCR4 (0.40) CCR4LMNA
SCHEMBL24596297 0.80 EPHX2 (0.47) EGFRL3MBTL1TSHRLMNATAS2R14
SCHEMBL24596390 0.80 LMNA (0.45) IGF1RTSHRLMNATAS2R14
SCHEMBL24596284 0.79 IGF1R (0.54) IGF1RTSHR
SCHEMBL24596349 0.78 CDK19 (0.46) EGFRJAK3L3MBTL1LMNAPOLB
SCHEMBL24596302 0.76 MAT2A (0.39) LMNATAS2R14
SCHEMBL24596243 0.76 LMNA (0.41) LMNATAS2R14
SCHEMBL24596343 0.75 SYK (0.37) IGF1RTSHRTAS2R14
SCHEMBL24596254 0.75 ENPP3 (0.35) IGF1RLMNATAS2R14
SCHEMBL24596400 0.74 IGF1R (0.42) IGF1RLMNATAS2R14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A CCR4 4523/4885PIK3CA 1903/4885PIK3CB 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.